DE60329219D1 - Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren - Google Patents
Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitorenInfo
- Publication number
- DE60329219D1 DE60329219D1 DE60329219T DE60329219T DE60329219D1 DE 60329219 D1 DE60329219 D1 DE 60329219D1 DE 60329219 T DE60329219 T DE 60329219T DE 60329219 T DE60329219 T DE 60329219T DE 60329219 D1 DE60329219 D1 DE 60329219D1
- Authority
- DE
- Germany
- Prior art keywords
- cyclooxygenase
- cox
- inhibitors
- derivatives
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title 2
- -1 AMINO Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42922202P | 2002-11-26 | 2002-11-26 | |
PCT/EP2003/013246 WO2004048314A1 (en) | 2002-11-26 | 2003-11-25 | Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60329219D1 true DE60329219D1 (de) | 2009-10-22 |
Family
ID=32393527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60329219T Expired - Lifetime DE60329219D1 (de) | 2002-11-26 | 2003-11-25 | Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren |
Country Status (15)
Country | Link |
---|---|
US (1) | US7202364B2 (de) |
EP (2) | EP2090566A3 (de) |
JP (2) | JP4580240B2 (de) |
CN (1) | CN1729157A (de) |
AR (1) | AR042206A1 (de) |
AT (1) | ATE442348T1 (de) |
AU (1) | AU2003292112A1 (de) |
BR (1) | BR0316615A (de) |
CA (1) | CA2507458A1 (de) |
DE (1) | DE60329219D1 (de) |
ES (1) | ES2333316T3 (de) |
PE (1) | PE20040844A1 (de) |
PT (1) | PT1567477E (de) |
TW (1) | TW200424152A (de) |
WO (1) | WO2004048314A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
US20070093476A1 (en) * | 2003-10-28 | 2007-04-26 | Bhunia Debnath | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them |
DK1773816T3 (en) | 2004-06-24 | 2015-01-26 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
DE102004044827A1 (de) | 2004-09-16 | 2006-03-23 | Bayer Cropscience Ag | Jod-phenylsubstituierte cyclische Ketoenole |
ATE517085T1 (de) | 2004-11-23 | 2011-08-15 | Astrazeneca Ab | Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate |
PT1928454E (pt) | 2005-05-10 | 2014-12-04 | Intermune Inc | Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress |
JP5155171B2 (ja) | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
AU2006303301A1 (en) * | 2005-10-18 | 2007-04-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
ATE545637T1 (de) * | 2005-12-15 | 2012-03-15 | Astrazeneca Ab | Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen |
JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
CN102731381B (zh) * | 2006-01-13 | 2016-08-17 | 美国陶氏益农公司 | 6-(多取代芳基)-4-氨基吡啶甲酸酯及其作为除草剂的用途 |
DE102006007882A1 (de) | 2006-02-21 | 2007-08-30 | Bayer Cropscience Ag | Cycloalkyl-phenylsubstituierte cyclische Ketoenole |
AR061623A1 (es) | 2006-06-26 | 2008-09-10 | Novartis Ag | Derivados de acido fenilacetico |
US20080139611A1 (en) * | 2006-10-17 | 2008-06-12 | Jan Wasley | Methods of using 4-phenylaminoquinolines as topical non-steroidal antiinflammatory compounds |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
EP2135610A1 (de) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Kombination mit DHODH-Inhibitoren und Methotrexat |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
EP2239256A1 (de) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Natriumsalz von 5-cyclopropyl-2-{[2-(2,6-difluorphenyl)pyrimidin-5-yl]amino}benzoesäure als DHODH-Inhibitor |
NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
EP2314577A1 (de) * | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Verfahren zur Herstellung von 2-[(3,5-Difluor-3'-methoxy-1,1'-biphenyl-4-yl)amino]nikotinsäure |
SI2522658T1 (sl) * | 2010-01-04 | 2018-12-31 | Nippon Soda Co., Ltd. | Dušik-vsebujoča heterociklična spojina in kmetijski/hortikulturni germicid |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
EP2531490B1 (de) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexylamidderivate als crf-rezeptorantagonisten |
AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
EP2852591A1 (de) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malatsalz aus 2,7-diaza-spiro[4.5]dec-7-yl-derivaten und kristalline formen davon als ghrelin-rezeptoragonisten |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
EP3590920A4 (de) * | 2017-03-02 | 2021-01-06 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 2-(substituierte benzolmatrix)-aromatischer format-fto-inhibitor, herstellungsverfahren dafür und anwendungen davon |
CN109721565B (zh) * | 2017-10-27 | 2020-09-15 | 都创(上海)医药科技有限公司 | 一种重要的氟中间体合成工艺 |
GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
CN113620874B (zh) * | 2021-08-10 | 2024-02-06 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2-三氟甲基-4-氨基-喹啉衍生物及其用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895063A (en) * | 1965-04-08 | 1975-07-15 | Ciba Geigy Corp | Substituted Anilino Benzyl Alcohols |
US3558690A (en) * | 1965-04-08 | 1971-01-26 | Gelgy Chemical Corp | Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation |
GB1166861A (en) * | 1966-01-15 | 1969-10-15 | Aspro Nicholas Ltd | New Diphenylamine Derivatives and Compositions containing them |
US3637710A (en) * | 1969-05-26 | 1972-01-25 | Geigy Chem Corp | 4-(phenylimino)-1 4-dihydroquinoline derivatives |
US3652762A (en) * | 1970-04-14 | 1972-03-28 | Ciba Geigy Corp | Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters |
US4173577A (en) * | 1970-09-09 | 1979-11-06 | Ciba-Geigy Corporation | Phenylacetohydroxamic acids |
JPS51149252A (en) * | 1975-06-14 | 1976-12-22 | Ikeda Mohandou:Kk | A process for preparing naphthylaminophenyl acetic acid derivatives |
JPS5268159A (en) * | 1975-12-03 | 1977-06-06 | Ikeda Mohando Co | Production of naphthyl aminophenyl acetic acid derivatives |
JPS5283822A (en) * | 1976-01-01 | 1977-07-13 | Ikeda Mohando Co | Naphthylaminopheny acetic acid derivatives and salts thereof* |
JPS5396434A (en) | 1977-02-03 | 1978-08-23 | Yokogawa Hokushin Electric Corp | Synchronizing rectifier circuit |
AT370721B (de) | 1981-02-24 | 1983-04-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen salzen der 2- (2,6-dichloranilino)-phenylessigsaeure, der |
ES8404783A1 (es) * | 1983-03-21 | 1984-05-16 | Prodes Sa | Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico. |
DE3445011A1 (de) | 1983-12-13 | 1985-06-13 | Ciba-Geigy Ag, Basel | Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung |
DE3612537C1 (de) | 1986-04-14 | 1987-07-16 | Dispersa Ag | Arzneimittel zur Behandlung von Entzuendungen im Auge |
US4960799A (en) | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
US5068250A (en) * | 1988-09-29 | 1991-11-26 | Trustees Of University Of Pennsylvania | Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites |
DE69223438T2 (de) | 1991-04-24 | 1998-06-04 | Koninkl Philips Electronics Nv | Abtasttaktrückwinnung für Empfänger, die Viterbi-Verarbeitung benutzen |
IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
GB9302071D0 (en) | 1993-02-03 | 1993-03-24 | Rhone Poulenc Agriculture | Compositions of matter |
HUT75341A (en) | 1994-06-29 | 1997-05-28 | Ciba Geigy Ag | New salts of 2-[(2,6-dichloro-phenyl)-amino]-phenyl-acetoxy-acetic acid with organic bases, pharmaceutical compns. contg. them and process for preparing the said compds. |
JPH0977664A (ja) * | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−2特異的阻害剤及び抗炎症剤 |
US6355680B1 (en) * | 1996-02-20 | 2002-03-12 | Exocell, Inc. | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
WO1998016227A1 (en) | 1996-10-15 | 1998-04-23 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
OA11958A (en) * | 1999-06-10 | 2006-04-13 | Warner Lambert Co | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives. |
GB9922830D0 (en) | 1999-09-27 | 1999-11-24 | Novartis Ag | Processes |
EP1246621A4 (de) | 1999-12-23 | 2004-11-24 | Nitromed Inc | Nitrosierte und nitrosylierte cyclooxygenase-2-inhibitoren, zusammensetzungen und methoden für deren verwendung |
PE20020351A1 (es) | 2000-09-11 | 2002-06-14 | Novartis Ag | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 |
AU2002306868A1 (en) | 2001-03-28 | 2002-10-15 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
AR042206A1 (es) * | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
-
2003
- 2003-11-24 AR ARP030104330A patent/AR042206A1/es unknown
- 2003-11-24 PE PE2003001186A patent/PE20040844A1/es not_active Application Discontinuation
- 2003-11-25 EP EP09160053A patent/EP2090566A3/de not_active Withdrawn
- 2003-11-25 DE DE60329219T patent/DE60329219D1/de not_active Expired - Lifetime
- 2003-11-25 BR BR0316615-5A patent/BR0316615A/pt not_active Application Discontinuation
- 2003-11-25 CN CNA200380107251XA patent/CN1729157A/zh active Pending
- 2003-11-25 AU AU2003292112A patent/AU2003292112A1/en not_active Abandoned
- 2003-11-25 AT AT03767652T patent/ATE442348T1/de not_active IP Right Cessation
- 2003-11-25 ES ES03767652T patent/ES2333316T3/es not_active Expired - Lifetime
- 2003-11-25 WO PCT/EP2003/013246 patent/WO2004048314A1/en active Application Filing
- 2003-11-25 JP JP2004554464A patent/JP4580240B2/ja not_active Expired - Fee Related
- 2003-11-25 PT PT03767652T patent/PT1567477E/pt unknown
- 2003-11-25 CA CA002507458A patent/CA2507458A1/en not_active Abandoned
- 2003-11-25 TW TW092133055A patent/TW200424152A/zh unknown
- 2003-11-25 EP EP03767652A patent/EP1567477B1/de not_active Expired - Lifetime
- 2003-11-25 US US10/724,457 patent/US7202364B2/en not_active Expired - Fee Related
-
2010
- 2010-04-01 JP JP2010085010A patent/JP2010159287A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20040132769A1 (en) | 2004-07-08 |
PT1567477E (pt) | 2009-12-14 |
BR0316615A (pt) | 2005-10-11 |
TW200424152A (en) | 2004-11-16 |
AR042206A1 (es) | 2005-06-15 |
US7202364B2 (en) | 2007-04-10 |
EP2090566A2 (de) | 2009-08-19 |
ATE442348T1 (de) | 2009-09-15 |
ES2333316T3 (es) | 2010-02-19 |
CA2507458A1 (en) | 2004-06-10 |
WO2004048314A1 (en) | 2004-06-10 |
EP2090566A3 (de) | 2009-08-26 |
EP1567477B1 (de) | 2009-09-09 |
JP2006507336A (ja) | 2006-03-02 |
AU2003292112A1 (en) | 2004-06-18 |
EP1567477A1 (de) | 2005-08-31 |
CN1729157A (zh) | 2006-02-01 |
JP4580240B2 (ja) | 2010-11-10 |
PE20040844A1 (es) | 2004-12-30 |
JP2010159287A (ja) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60329219D1 (de) | Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren | |
DE50312295D1 (de) | 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel | |
DE60325761D1 (de) | Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren | |
ATE425979T1 (de) | Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel | |
DE50312747D1 (de) | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
DE60336907D1 (de) | Spirobifluorenderivate, deren herstellung und deren verwendung | |
DE60233825D1 (de) | BENZOATESÄURE-2-(a-HYDROXYPENTYL)ESTER UND DESSEN HERSTELLUNG UND VERWENDUNG | |
DE50209483D1 (de) | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
DE69816651D1 (de) | 2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren | |
CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
EE200500011A (et) | Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine | |
ATE395339T1 (de) | Biphenylderivate und deren verwendung als fungizide | |
ATE489382T1 (de) | Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel | |
DE60209779D1 (de) | Sulfonamidderivate, deren herstellung und deren verwendung als medikamente | |
DE60200427D1 (de) | Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung | |
DE60336266D1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten | |
ATE551329T1 (de) | Chinazolinonderivate und deren verwendung als cb- agonisten | |
ATE250045T1 (de) | Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel | |
DE60322551D1 (de) | 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren | |
DE50305374D1 (de) | Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel | |
DE60321372D1 (de) | 3-phenylpyridoindolderivate, ihre herstellung und verwendung | |
DE602004015600D1 (de) | Neue imidazolderivative, deren herstellung und deren verwendung als medikament | |
DE60322408D1 (de) | Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
ATE353083T1 (de) | Naphthyridin-derivate und ihre verwendung als fungizide | |
ATE329908T1 (de) | Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH |
|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 1567477 Country of ref document: EP Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE |